You are here

The Progress Report Progress never stops. Stay informed with the latest news on breast cancer research, treatment, and prevention.


Liquid Biopsy x

A liquid biopsy is commonly used in clinical and laboratory research to identify and measure biomarkers. Several sessions at the 2019 AACR Annual Meeting in Atlanta were dedicated to this topic.

Advances over the last 10 to 15 years in DNA sequencing technologies revolutionized our understanding of cancer as a disease resulting from deleterious alterations to DNA. By identifying cancer driving genes, this work fueled research in targeted treatment and prevention strategies.

At BCRF we are proud to play a part in projects that lead to breakthroughs in breast cancer. With over 250 investigators that the Foundation supports, there are constantly new developments in all fields of research. One area showing exciting progress is the advancement of liquid biopsies.

Scientists do not fully understand why tumor cells become resistant to therapy, but current research supports the possibility that it involves treatment-induced molecular or genetic changes that reprogram the cell, allowing it to survive in the presence of drugs.

A blood-based test, measuring what is called cell-free DNA in blood plasma, identified mutations in the estrogen receptor gene, called ESR1, in 30

In January of this year, the American Association for Cancer Research (AACR) released a special report outlining its view on how cancer prevention will change in the era of precision medicine and immune-oncology.

Dr. Park’s research at Johns Hopkins focuses on finding mutated or altered genes responsible for breast cancer initiation and growth or resistance to anti-cancer drugs.